Cooper Companies (NYSE: COO) and TearLab Corporation (OTCMKTS:TEAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Cooper Companies and TearLab Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cooper Companies 16.45% 16.00% 9.90%
TearLab Corporation -60.22% N/A -75.54%

Earnings & Valuation

This table compares Cooper Companies and TearLab Corporation’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Cooper Companies $1.97 billion 6.03 $273.91 million $6.97 34.76
TearLab Corporation $28.01 million 0.15 -$19.92 million ($2.98) -0.24

Cooper Companies has higher revenue and earnings than TearLab Corporation. TearLab Corporation is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.2% of Cooper Companies shares are held by institutional investors. Comparatively, 19.8% of TearLab Corporation shares are held by institutional investors. 1.6% of Cooper Companies shares are held by company insiders. Comparatively, 12.0% of TearLab Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dividends

Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab Corporation does not pay a dividend. Cooper Companies pays out 0.9% of its earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current ratings and target prices for Cooper Companies and TearLab Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies 0 5 7 0 2.58
TearLab Corporation 0 0 4 0 3.00

Cooper Companies currently has a consensus price target of $260.63, suggesting a potential upside of 7.57%. TearLab Corporation has a consensus price target of $5.75, suggesting a potential upside of 709.86%. Given TearLab Corporation’s stronger consensus rating and higher possible upside, analysts plainly believe TearLab Corporation is more favorable than Cooper Companies.

Volatility and Risk

Cooper Companies has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, TearLab Corporation has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500.

Summary

Cooper Companies beats TearLab Corporation on 10 of the 15 factors compared between the two stocks.

About Cooper Companies

The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.